UnknownPhase 3NCT00683124

Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients

Studying Marfan syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Principal Investigator
Eloisa Arbustini, MD,FESC,FACC
IRCCS Foundation San Matteo Hospital, Pavia
Intervention
Losartan and nebivolol(drug)
Enrollment
291 enrolled
Eligibility
55 years · All sexes
Timeline
2008 – 2013

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC · Menarini Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00683124 on ClinicalTrials.gov

Other trials for Marfan syndrome

Additional recruiting or active studies for the same condition.

See all trials for Marfan syndrome →

← Back to all trials